Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment
Authors:
- Jessica WagnerJWJessica Wagner
- C. Leah KlineCKC. Leah Kline
- Lanlan ZhouLZLanlan Zhou
- Kerry S. CampbellKCKerry S. Campbell
- Alexander W. MacFarlaneAMAlexander W. MacFarlane
- Anthony J. OlszanskiAOAnthony J. Olszanski
- Kathy Q. CaiKCKathy Q. Cai
- Harvey H. HensleyHHHarvey H. Hensley
- Eric A. RossEREric A. Ross
- Marie D. RalffMRMarie D. Ralff
- Andrew ZlozaAZAndrew Zloza
- Charles B. ChessonCCCharles B. Chesson
Open Access
- 30 April 2018
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 128 (6) , 2325-2338
Abstract
ONC201 is a first-in-class, orally active antitumor agent that upregulates cytotoxic TRAIL pathway signaling in cancer cells. ONC201 has demonstrated safety and preliminary efficacy in a first-in-human trial in which patients were dosed every 3 weeks. We hypothesized that dose intensification of ONC201 may impact antitumor efficacy. We discovered that ONC201 exerts dose- and schedule-dependent effects on tumor progression and cell death signaling in vivo. With dose intensification, we note a potent anti-metastasis effect and inhibition of cancer cell migration and invasion. Our preclinical results prompted a change in ONC201 dosing in all open clinical trials. We observed accumulation of activated NK+ and CD3+ cells within ONC201-treated tumors and that NK cell depletion inhibits ONC201 efficacy in vivo, including against TRAIL/ONC201-resistant Bax–/– tumors. Immunocompetent NCR1-GFP mice, in which NK cells express GFP, demonstrated GFP+ NK cell infiltration of syngeneic MC38 colorectal tumors. Activation of primary human NK cells and increased degranulation occurred in response to ONC201. Coculture experiments identified a role for TRAIL in human NK-mediated antitumor cytotoxicity. Preclinical results indicate the potential utility for ONC201 plus anti–PD-1 therapy. We observed an increase in activated TRAIL-secreting NK cells in the peripheral blood of patients after ONC201 treatment. The results offer what we believe to be a unique pathway of immune stimulation for cancer therapy.Keywords
Funding Information
- National Institutes of Health (CA173453)
- American Cancer Society (RP-14-233-07-COUN)
This publication has 33 references indexed in Scilit:
- Cancer Immunosurveillance and Immunoediting by Natural Killer CellsThe Cancer Journal, 2013
- Strength of PD-1 signaling differentially affects T-cell effector functionsProceedings of the National Academy of Sciences, 2013
- Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor EffectsScience Translational Medicine, 2013
- Enhancement of natural killer cell effector functions against selected lymphoma and leukemia cell lines by dasatinibInternational Journal of Cancer, 2012
- NKG2D signaling on CD8+ T cells represses T-bet and rescues CD4-unhelped CD8+ T cell memory recall but not effector responsesNature Medicine, 2012
- Mechanistic modeling of the effects of myoferlin on tumor cell invasionProceedings of the National Academy of Sciences, 2011
- NK cell development, homeostasis and function: parallels with CD8+ T cellsNature Reviews Immunology, 2011
- Natural Killer Cells in Human Cancer: From Biological Functions to Clinical ApplicationsBioMed Research International, 2011
- Analysis of Death Receptor 5 and Caspase-8 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma and Their Prognostic ImpactPLOS ONE, 2010
- TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor developmentJournal of Clinical Investigation, 2008